| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2008-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fec23b4c5f7e71b7c2e24e8ce2d3081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17ec5eee90557f4d4b1c1cfe34e8ca83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80659d7ad248d0f50c0cd2331ced1b14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c295708d366be0d91cd5ea608e07342 |
| publicationDate |
2009-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20090114454-A |
| titleOfInvention |
Cancer disease regulatory antibody produced by the hybridoma cell line AR5011A630.3. |
| abstract |
The present invention is directed to methods of producing cancer disease modulating antibodies using the novel screening paradigm. The method allows the preparation of anti-cancer antibodies for therapeutic and diagnostic purposes by separating anti-cancer antibodies using cancer cell cytotoxicity as a endpoint. The antibodies can be used to aid in staging and diagnosis of cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibody can bind to toxins, enzymes, radioactive compounds and hematopoietic cells. |
| priorityDate |
2007-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |